The Significance of Vaccines in Mitigating Emerging Infectious Diseases: A Comprehensive Review
Keywords:
Vaccination, Emerging Infectious Diseases, Antimicrobial Resistance, Immunotherapy, Public Health.Abstract
Background: The global rise in emerging infectious diseases presents significant challenges to public health, exacerbated by issues such as antimicrobial resistance (AMR). Vaccination remains a pivotal strategy in preventing the spread of these diseases, yet its role is often underappreciated in the context of rising drug resistance.
Methods: This review synthesizes current literature on the effectiveness of vaccines and immunotherapeutic approaches in controlling emerging infectious diseases. It analyzes data from clinical studies, epidemiological reports, and the impact of vaccination on AMR trends, particularly in regions severely affected by infectious diseases.
Results: Findings indicate that vaccines significantly reduce the incidence and severity of diseases such as tuberculosis, malaria, and COVID-19. Furthermore, immunotherapy, including monoclonal antibodies, demonstrates potential in enhancing host immunity against multidrug-resistant pathogens. Despite advancements, the ongoing rise of AMR, particularly in low- and middle-income countries, poses a considerable threat to the efficacy of existing vaccines and treatments.
Conclusion: Vaccination and immunotherapeutic strategies are essential components in the fight against emerging infectious diseases and AMR. Continued investment in vaccine development and implementation is critical to mitigate the impact of these evolving health threats. Future research should focus on innovative vaccine technologies and strategies to enhance public health responses in vulnerable populations.
References
1. Dikid T, Jain S, Sharma A, Kumar A, Narain J. Emerging and re-emerging infections in India: an overview. Indian J Med Res. (2013) 138:19–31.
2. Cohen ML. Changing patterns of infectious disease. Nature. (2000) 406:762–7.
3. Cupertino MC, Resende MB, Mayer NA, Carvalho LM, Siqueira-Batista R. Emerging and re-emerging human infectious diseases: a systematic review of the role of wild animals with a focus on public health impact. Asian Pac J Trop Med. (2020) 13:99.
4. Manesh A, Varghese GM. Rising antimicrobial resistance: an evolving epidemic in a pandemic. Lancet Microbe. (2021) 2:e419–20.
5. O’Neill J. Tackling Drug-resistant Infections Globally: Final Report and Recommendations (2016).
6. 6.Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. (2015) 109:309–18.
7. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. (2017) 6:47–8.
8. Mohamed A, Hassan T, Trzos-Grzybowska M, Thomas J, Quinn A, O'Sullivan M, et al. Multi-triazole-resistant aspergillus fumigatus and SARS-CoV-2 co-infection: a lethal combination. Med Mycol Case Rep. (2021) 31:11–4.
9. Posteraro B, Torelli R, Vella A, Leone PM, de Angelis G, de Carolis E, et al. Pan-echinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: a fatal case report. J Fungi. (2020) 6:163.
10. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. (2020) 9:1–7.
11. Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. (2020) 10:1–9.
12. Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R, van de Veerdonk FL, et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cells. (2020) 181:969–77.
13. Lai C-C, Chen S-Y, Ko W-C, Hsueh P-R. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. (2021) 57:106324.
14. Nicholson LB. The immune system. Essays Biochem. (2016) 60:275–301.
15. Mir MA, Bhat BA, Sheikh BA, Rather GA, Mehraj S, Mir WR. “Nanomedicine in human health therapeutics and drug delivery: nanobiotechnology and nanobiomedicine,” in Applications of Nanomaterials in Agriculture, Food Science, and Medicine. IGI Global (2021) 229–51.
16. Mir MA, Albaradie RS. Inflammatory mechanisms as potential therapeutic targets in stroke. Adv. Neuroimmune Biol. (2014) 5:199–216.
17. Mir MA, Al-baradie R. Tuberculosis time bomb-A global emergency: Need for alternative vaccines. J. Health Sci. (2013) 1:77–82.
18. Mir MA, Agrewala JN. Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells. Curr. Immunol. Rev. (2007) 3:160–9.
19. Mir M, Albaradeh R, Agrewala J. (2013). Innate–effector immune response elicitation against tuberculosis through anti-b7-1 (CD80) and anti-b7-2 (CD86) signaling in macrophages.
20. Mir M. Introduction to costimulation and costimulatory molecules. Developing costimulatory molecules for immunotherapy of diseases. (2015):1–43.
21. Mir MA, Qadri UJH. Significance of immunotherapy for human fungal diseases and antifungal drug discovery. Elsevier; (2022).
22. Mir MA, Qadri SSHH. Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery. Elsevier; (2022).
23. Qadri H, Shah AH, Mir M. Novel strategies to combat the emerging drug resistance in human pathogenic microbes. Curr Drug Targets. (2021) 22:1424–36.
24. Qadri H, Qureshi MF, Mir MA, Shah AH. Glucose-The X factor for the survival of human fungal pathogens and disease progression in the host. Microbiol. Res. (2021) 247:126725.
25. Qadri H, Shah AH, Andrabi SM, Alshehri B, Almilaibary A, Mir MA. Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi. Saudi J. Biol. Sci. (2022) 18:103376.
26. McKeegan KS, Borges-Walmsley MI, Walmsley AR. Microbial and viral drug resistance mechanisms. Trends Microbiol. (2002) 10:s8–s14.
27. Collignon P. Clinical impact of antimicrobial resistance in humans. Rev Sci Tech. (2012) 31:211–20.
28. Mir MA, Qadri SAH, Jan U, Yousuf A, Jan N. Evolution of antimicrobial drug resistance in human pathogenic bacteria. Elsevier; (2022).
29. Mir MA. Evolution of antimicrobial drug resistance in human pathogenic fungi. Elsevier; (2022).
30. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. (2015) 40:277–83.
31. Mandal S, Mandal MD, Pal NK. Cholera: a great global concern. Asian Pac J Trop Med. (2011) 4:573–80.
32. Vila J, Pal T. Update on antibacterial resistance in low-income countries: factors favoring the emergence of resistance. Open Infect Dis J. (2010) 4:38–54.
33. Cohen KA, Manson AL, Desjardins CA, Abeel T, Earl AM. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med. (2019) 11:1–18.
34. Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. (2017) 41:354–73.
35. Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci. (2021) 22:3128.
36. Moradali MF, Ghods S, Rehm BH. Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol. (2017) 7:39.
37. Tigabu A, Getaneh A. Staphylococcus aureus, ESKAPE bacteria challenging current health care and community settings: a literature review. Clin Lab. (2021) 67:7754.
38. Caneiras C, Lito L, Melo-Cristino J, Duarte A. Community-and hospital-acquired Klebsiella pneumoniae urinary tract infections in Portugal: virulence and antibiotic resistance. Microorganisms. (2019) 7:138.
39. Eghbalpoor F, Habibi M, Azizi O, Asadi Karam MR, Bouzari S. Antibiotic resistance, virulence and genetic diversity of Klebsiella pneumoniae in community-and hospital-acquired urinary tract infections in Iran. Acta Microbiol Immunol Hung. (2019) 66:349–66.
40. García-Solache M, Rice LB. The Enterococcus: a model of adaptability to its environment. Clin Microbiol Rev. (2019) 32:e00058–18.
41. Jabbari Shiadeh SM, Pormohammad A, Hashemi A, Lak P. Global prevalence of antibiotic resistance in blood-isolated Enterococcus faecalis and Enterococcus faecium: a systematic review and meta-analysis. Infect Drug Resist. (2019):2713–25.
42. Zaman S. A review on antibiotic resistance: alarm bells are ringing. Cureus. (2017) 9:e1403–3.
43. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. (2018) 4:482.
44. Sandner-Miranda L, Vinuesa P, Cravioto A, Morales-Espinosa R. The genomic basis of intrinsic and acquired antibiotic resistance in the genus Serratia. Front Microbiol. (2018) 9:828.
45. Ben Y, Fu C, Hu M, Liu L, Wong MH, Zheng C. Human health risk assessment of antibiotic resistance associated with antibiotic residues in the environment: a review. Environ Res. (2019) 169:483–93.
46. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. (2015) 5:a019752.
47. Kontoyiannis DP. Antifungal resistance: an emerging reality and a global challenge. J Infect Dis. (2017) 216:S431–5.
48. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases–estimate precision. J Fungi. (2017) 3:57.
49. Redhu AK, Shah AH, Prasad R. MFS transporters of Candida species and their role in clinical drug resistance. FEMS Yeast Res. (2016) 16:fow043.
50. Bassetti M, Peghin M, Timsit J-F. The current treatment landscape: candidiasis. J Antimicrob Chemother. (2016) 71:ii13–22.
51. Ksiezopolska E, Gabaldón T. Evolutionary emergence of drug resistance in Candida opportunistic pathogens. Genes. (2018) 9:461.
52. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi. (2007) 48:1–12.
53. McCarty TP, Pappas PG. Invasive candidiasis. Infect Dis Clin. (2016) 30:103–24.
54. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. (2018) 4:1–20.
55. Chabi M, Goracci A, Roche N, Paugam A, Lupo A, Revel M. Pulmonary aspergillosis. Diagn Interv Imaging. (2015) 96:435–42.
56. Latgé J-P, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev. (2019) 33:e00140–18.
57. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin. (2016) 30:179–206.
58. Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, et al. The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. MSphere. (2017) 2:e00357–16.
59. Kathiravan MK, Salake AB, Chothe AS, Dudhe PB, Watode RP, Mukta MS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem. (2012) 20:5678–98.
60. Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. (2016) 4:261.
61. Datta K, Hamad M. Immunotherapy of fungal infections. Immunol Investig. (2015) 44:738–76.
62. Ecker DM, Jones SD, Levine HL. The Therapeutic Monoclonal Antibody Market MAbs. Abingdon: Taylor & Francis; (2015).
63. Casadevall A, Pirofski L-a. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe. (2012) 11:447–56.
64. Casadevall A, Dadachova E, Pirofski L-a. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. (2004) 2:695–703.
65. Schwab M. Encyclopedia of Cancer. Berlin, Germany: Springer Science and Business Media; (2008).
66. Naran K, Nundalall T, Chetty S, Barth S. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. Front Microbiol. (2018) 9:3158.
67. Klein EY, van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci. (2018) 115:E3463–70.
68. O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations (2014).
69. Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic resistance. Clin Microbiol Infect. (2016) 22:416–22.
70. Fernandes P, Martens E. Antibiotics in late clinical development. Biochem Pharmacol. (2017) 133:152–63.
71. Sheikh BA, Bhat BA, Mir MA. Antimicrobial resistance: new insights and therapeutic implications. Applied Microbiology and Biotechnology. (2022) 106:6427–40.
72. Qadri H, Shah AH, Mir MA. “Role of immunogenetics polymorphisms in infectious diseases,” in A Molecular Approach to Immunogenetics. Elsevier; (2022) 169–191.
73. Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. Nat Rev Microbiol. (2017) 15:453–64.
74. McCulloch TR, Wells TJ, Souza-Fonseca-Guimaraes F. Towards efficient immunotherapy for bacterial infection. Trends Microbiol. (2022) 30:158–69.
75. Motley MP, Banerjee K, Fries BC. Monoclonal antibody-based therapies for bacterial infections. Curr Opin Infect Dis. (2019) 32:210.
76. Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, et al. A functional role for antibodies in tuberculosis. Cells. (2016) 167:433–443.e14.
77. Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, et al. Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. (2019) 25:629.
78. Tabor D, Oganesyan V, Keller A, Yu L, McLaughlin R, Song E, et al. Pseudomonas aeruginosa PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates. J Infect Dis. (2018) 218:1983–94.
79. François B, Mercier E, Gonzalez C, Asehnoune K, Nseir S, Fiancette M, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. (2018) 44:1787–96.
80. Ruzin A, Wu Y, Yu L, Yu XQ, Tabor DE, Mok H, et al. Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin. Clin Transl Immunol. (2018) 7:e1009
81. World Health Organization . Global Tuberculosis Report 2021. Licence: CC BY-NC-SA 30 IGO. Geneva: World Health Organization (2020).
82. Sable SB, Posey JE, Scriba TJ. Tuberculosis vaccine development: progress in clinical evaluation. Clin Microbiol Rev. (2019) 33:e00100–19.
83. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. (2015) 3:190–200.
84. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. (2013) 381:1021–8.
85. Tait DR, Hatherill M, van der Meeren O, Ginsberg AM, van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. (2019) 381:2429–39.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
CC Attribution 4.0
